Search hospitals > District of Columbia > Washington
Children's National Medical Center
Claim this profileWashington, District of Columbia 20010
Global Leader in Cancer
Global Leader in Brain Tumor
Conducts research for Adult T-Cell Leukemia/Lymphoma
Conducts research for Solid Tumors
Conducts research for Relapse
1070 reported clinical trials
71 medical researchers
Summary
Children's National Medical Center is a medical facility located in Washington, District of Columbia. This center is recognized for care of Cancer, Brain Tumor, Adult T-Cell Leukemia/Lymphoma, Solid Tumors, Relapse and other specialties. Children's National Medical Center is involved with conducting 1,070 clinical trials across 1,379 conditions. There are 71 research doctors associated with this hospital, such as Jeffrey S. Dome, AeRang Kim, MD, PhD, Eugene Hwang, MD, and Lindsay Kilburn, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Brain Tumor
Global LeaderStage IV
BRAF positive
Stage II
Top PIs
Jeffrey S. DomeChildren's National Medical Center8 years of reported clinical research
Expert in Cancer
Expert in Brain Tumor
67 reported clinical trials
116 drugs studied
AeRang Kim, MD, PhDChildren's National Medical Center6 years of reported clinical research
Expert in Cancer
Studies Soft Tissue Sarcoma
24 reported clinical trials
39 drugs studied
Eugene Hwang, MDChildren's National Medical Center5 years of reported clinical research
Expert in Brain Tumor
Studies Diffuse Intrinsic Pontine Glioma
21 reported clinical trials
32 drugs studied
Lindsay Kilburn, MDChildren's National Medical Center5 years of reported clinical research
Expert in Brain Tumor
Studies Relapse
15 reported clinical trials
24 drugs studied
Clinical Trials running at Children's National Medical Center
Acute Lymphoblastic Leukemia
Sickle Cell Disease
Cancer
Wilms Tumor
Testicular cancer
Brain Tumor
Adult T-Cell Leukemia/Lymphoma
Hypercholesterolemia
Solid Tumors
Kidney Disorders
Targeted Immunotherapy
for Leukemia
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.
Recruiting2 awards Phase 17 criteria
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Children's National Medical Center?
Where is Children's National Medical Center located?
Who should I call to ask about financial aid or insurance network?
What insurance does Children's National Medical Center accept?
What awards or recognition has Children's National Medical Center received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.